Valneva, Serum Institute of India discontinue chikungunya vaccine pact

Valneva (VALN) and Serum Institute of India announced that they have mutually agreed to discontinue their license agreement for Valneva’s single-shot chikungunya vaccine. “Valneva’s strategic intent in regaining full rights is to assume direct control over its supply chain and commercialization for endemic high-risk countries, thereby accelerating access for regions most affected by the disease. Supporting access to the vaccine in low-and-middle-income countries falls within the framework of the funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations in July 2024 with co-funding from the European Union,” the company stated.